Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Neoplasms by Site
Clear Filters

Search Clinical Trials

35 Results
Not Yet Recruiting
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
The study team will collect up to 18 teaspoons of patients' blood. This will be used this blood to grow T cells. The study team then grows the T cells …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies
This study will examine both Human papillomavirus (HPV) vaccine effectiveness and Primary high-risk HPV PHS screening triage strategies in women living with HIV (WLHIV) by partnering with the Pediatric HIV/AIDs …
Baylor Role: Collaborator
Recruiting
Emergency Room HPV Self-Sampling Study (ACT NOW)
The goal of this study is to develop and evaluate an evidence-based public health intervention using HPV self-sampling approach in an opportunistic setting to increase cervical cancer screening among screening …
Baylor Role: Lead Sponsor
Terminated
Clinical Performance Evaluation of the C2i-Test
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome …
Baylor Role: Collaborator
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Approximately 118-27 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (approximately 12 tablespoons) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Recruiting
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
In most cases, patients who have early stage endometrial cancer undergo a surgery to remove the uterus, cervix, tubes, ovaries, and occasionally lymph nodes. This is usually done through a …
Enrolling By Invitation
Prospective Evaluation of Self-Testing to Increase Screening
Regularly attending for Pap test cervical cancer screening in a clinic is often unfeasible and/or unacceptable to many women. Using mailed self-sampling kits to test for high-risk human papillomavirus (HPV), …
Baylor Role: Lead Sponsor
Recruiting
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
This is a single arm study in metastatic hormone naïve prostate cancer. Standard of care in these men is either to offer Androgen deprivation therapy (ADT) + abiraterone acetate/low-dose prednisone …